Improving cancer patients' prognosis by incorporating mindfulness intervention into the treatment strategy.

Combining the chemotherapy drug epirubicin with mindfulness interventions improves immune function, reduces tumor markers, lessens depression severity, enhances quality of life, alleviates cancer-related fatigue, and increases nursing satisfaction in patients with urinary system tumors and depression, compared to standard care with mitomycin. The study included 110 patients and notes limitations including a small sample size and short duration. The findings suggest that integrating mindfulness interventions into cancer treatment can address both physical and psychological distress.

Study at a glance

Abstract

This letter discusses the study by Liu et al recently published in World Journal of Psychiatry, which examines the benefits of combining epirubicin (EPI) with mindfulness interventions for patients with urinary system tumors and depression. The study included 110 patients and compared an experimental group receiving EPI and a mindfulness intervention strategy with a control group treated with mitomycin and standard care. Results showed that the experimental group had significant improvements in immune function, tumor markers, depression severity, quality of life, cancer-related fatigue, and nursing satisfaction. Despite acknowledging the study limitations such as a relatively small sample size and a short duration, the study highlights the efficacy of integrating mindfulness interventions into cancer treatment strategies to enhance patient outcomes and address psychological distress.